Shingrix, a shingles vaccine with emerging evidence linking it to reduced dementia risk, has officially launched in South Africa.
The arrival of the vaccine marks a significant development for public health in the region, offering a more effective alternative to previous options for preventing the painful viral infection.
The potential cognitive benefits have drawn particular attention from researchers and health advocates.
Studies suggest that the vaccine may lower the risk of dementia, adding a compelling layer to its value proposition beyond shingles prevention.
This dual benefit could influence adoption rates among older demographics, who are the primary target group for both conditions.
However, accessibility remains a concern.